Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Down-regulation of Bax-interacting factor 1 in human pancreatic ductal adenocarcinoma.

Coppola D, Helm J, Ghayouri M, Malafa MP, Wang HG.

Pancreas. 2011 Apr;40(3):433-7. doi: 10.1097/MPA.0b013e318205eb03.

2.

Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma.

Coppola D, Khalil F, Eschrich SA, Boulware D, Yeatman T, Wang HG.

Cancer. 2008 Nov 15;113(10):2665-70. doi: 10.1002/cncr.23892.

3.

Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.

Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H.

Mod Pathol. 2012 Jan;25(1):112-21. doi: 10.1038/modpathol.2011.142.

4.

Prognostic significance of autophagy-related protein expression in resected pancreatic ductal adenocarcinoma.

Ko YH, Cho YS, Won HS, Jeon EK, An HJ, Hong SU, Park JH, Lee MA.

Pancreas. 2013 Jul;42(5):829-35. doi: 10.1097/MPA.0b013e318279d0dc.

PMID:
23429496
5.

Stage-stratified analysis of prognostic significance of Bax-interacting factor-1 expression in resected colorectal cancer.

Ko YH, Cho YS, Won HS, An HJ, Sun DS, Hong SU, Park JH, Lee MA.

Biomed Res Int. 2013;2013:329839. doi: 10.1155/2013/329839.

6.

Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.

Zheng J, Huang S, Huang Y, Song L, Yin Y, Kong W, Chen X, Ouyang X.

Tumour Biol. 2016 Jun;37(6):7853-9. doi: 10.1007/s13277-015-4675-5.

PMID:
26695153
7.

Bax-interacting factor-1 expression in prostate cancer.

Coppola D, Oliveri C, Sayegh Z, Boulware D, Takahashi Y, Pow-Sang J, Djeu JY, Wang HG.

Clin Genitourin Cancer. 2008 Sep;6(2):117-21. doi: 10.3816/CGC.2008.n.018.

8.

Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma.

Foo WC, Rashid A, Wang H, Katz MH, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Fleming JB, Wang H.

Hum Pathol. 2013 Jun;44(6):1024-30. doi: 10.1016/j.humpath.2012.09.001.

9.

Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma.

Kim HS, Kim GY, Lim SJ, Kim YW.

Pathology. 2010 Dec;42(7):655-60. doi: 10.3109/00313025.2010.522172.

PMID:
21080875
10.

Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.

Zhao L, Cui Q, Lu Z, Chen J.

Pancreas. 2012 Mar;41(2):206-11. doi: 10.1097/MPA.0b013e318223d1a5.

PMID:
21792082
11.

Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.

Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, Goggins MS, Abbruzzese JL, Maitra A, Ho L.

Mod Pathol. 2007 May;20(5):570-8.

12.

Decreased circadian component Bmal1 predicts tumor progression and poor prognosis in human pancreatic ductal adenocarcinoma.

Li W, Liu L, Liu D, Jin S, Yang Y, Tang W, Gong L.

Biochem Biophys Res Commun. 2016 Mar 25;472(1):156-62. doi: 10.1016/j.bbrc.2016.02.087.

PMID:
26915801
13.

Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas.

Lee JW, Jeong EG, Soung YH, Nam SW, Lee JY, Yoo NJ, Lee SH.

Pathology. 2006 Aug;38(4):312-5.

PMID:
16916719
14.

Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.

Piao J, Liu S, Xu Y, Wang C, Lin Z, Qin Y, Liu S.

Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003.

PMID:
25445504
15.

HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma.

Hristov AC, Cope L, Di Cello F, Reyes MD, Singh M, Hillion JA, Belton A, Joseph B, Schuldenfrei A, Iacobuzio-Donahue CA, Maitra A, Resar LM.

Mod Pathol. 2010 Jan;23(1):98-104. doi: 10.1038/modpathol.2009.139.

16.

Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma.

Mahipal A, Mcdonald MJ, Witkiewicz A, Carr BI.

Med Oncol. 2012 Mar;29(1):134-9. doi: 10.1007/s12032-010-9802-y.

PMID:
21264542
17.

Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.

Jin A, Xu Y, Liu S, Jin T, Li Z, Jin H, Lin L, Lin Z.

Exp Mol Pathol. 2014 Feb;96(1):54-60. doi: 10.1016/j.yexmp.2013.11.003.

PMID:
24263054
18.

Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.

Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY, Wu YM, Lu YF, Yu LH, Li JP, Li ZS.

Tumour Biol. 2013 Apr;34(2):895-9. doi: 10.1007/s13277-012-0624-8.

PMID:
23247867
19.

MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.

Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA.

Clin Cancer Res. 2012 Jan 15;18(2):534-45. doi: 10.1158/1078-0432.CCR-11-0679.

20.

TRIM29 as a novel biomarker in pancreatic adenocarcinoma.

Sun H, Dai X, Han B.

Dis Markers. 2014;2014:317817. doi: 10.1155/2014/317817.

Supplemental Content

Support Center